A Randomized, Double-Blind, Placebo-Controlled, Phase 1 2a Trial Protocol to Assess the Safety and Efficacy of TAK-101 Administered by Microneedles in Patients With Celiac Disease. PPCR 2022, 8 (3), 37-48. https://doi.org/10.21801/ppcrj.2022.83.5.